Call Us: 888-488-5750

Seeing the future of self-insurance

VativoRx recently participated in the SIIA Future Leaders Forum in April 2022.

The goal of the Forum: Identify both the issues and opportunities for self-insurance in the coming years, and the people who are best-suited to help the industry address those opportunities.

The Forum saluted the people who got the self-insurance industry to its current position while beginning the important conversations around what comes next. 

VativoRx was proud to send one of our best people to the conference: Rosalyn Banks.

As director of PBM Programs & Services at VativoRx, Rosalyn oversees our company operations, the daily operations of staff and supervises all aspects of prescription benefit management (PBM) functions. This includes claims processing, plan management, customer service, client management, consulting resources, Rx audits & fraud/abuse identification and drug utilization review programs.

Rosalyn reports it was energizing to be around so many people in one place that are focused intently on the future.

Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »